Plain-English translation of NCT06814496 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new combination approach for people with advanced cancers that no longer respond to standard treatments. The trial combines radiation therapy with a medication called , which works by boosting your immune system to fight cancer cells. Researchers want to learn whether giving these two treatments together is safe and effective.
Many patients with certain types of advanced cancer run out of treatment options when their disease stops responding to standard therapies. This trial exists because early research suggests that combining radiation with this immunotherapy medication might help the immune system attack these hard-to-treat cancers more effectively.
You likely qualify if…
You likely don't qualify if…
You will receive the medication starting with a lower dose that gradually increases over the first few weeks, then continuing every two weeks. Radiation therapy will begin after the medication has been given for a couple of weeks and will target one area of your cancer. The entire treatment period lasts up to 24 months, with regular visits to monitor how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States